Targeting TUBB2B inhibits triple-negative breast cancer growth and brain-metastatic colonization

Qingling He1,2, Jianyang Hu1,2, Fung-Yin Ngo3

  • 1Department of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Kowloon Tong, Hong Kong.

Abstract

Insights

Triple-negative breast cancer (TNBC) overexpresses TUBB2B, promoting tumor survival and brain metastasis. Targeting TUBB2B with siRNA-gold nanoparticles offers a promising therapeutic strategy for TNBC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) presents significant treatment challenges due to its aggressive nature and high propensity for brain metastasis.
  • The β-tubulin isoform TUBB2B is overexpressed in TNBC, but its specific role in cancer progression and metastasis is not well understood.

Purpose of the Study:

  • To investigate TUBB2B as a potential therapeutic target in TNBC.
  • To elucidate the mechanisms by which TUBB2B contributes to TNBC growth and brain metastasis.

Main Methods:

  • Bioinformatics analysis of patient data to correlate TUBB2B expression with survival.
  • RNAscope in situ hybridization to assess TUBB2B expression in clinical samples.
  • In vitro and in vivo assays to evaluate the effects of TUBB2B knockdown on TNBC.
  • Mass spectrometry and biochemical experiments to identify interacting partners and mechanisms.
  • Preclinical xenograft studies using siRNA-gold nanoparticles (siRNA-AuNP) to test therapeutic efficacy.

Main Results:

  • TUBB2B is frequently overexpressed in TNBC tumors and brain metastases, correlating with poor patient prognosis.
  • TUBB2B knockdown inhibits TNBC cell survival and brain metastasis.
  • TUBB2B interacts with eEF1A1, suggesting a role in translational regulation.
  • A feed-forward loop involving TUBB2B in TNBC cells and astrocytes promotes brain metastatic colonization.
  • siRNA-AuNP targeting of TUBB2B effectively inhibited tumor growth and brain metastasis in preclinical models.

Conclusions:

  • TUBB2B is a novel therapeutic target in TNBC.
  • Targeting TUBB2B is a promising strategy for inhibiting TNBC cell survival and brain metastasis.
  • siRNA-AuNP delivery of TUBB2B-targeting agents shows potential for clinical application in TNBC treatment.